Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Chief Development Officer | September 01, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date September 01, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,313 |
Last balance in matching sequence
After 2026-09-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-01 · Grant · Acquired 164 · Balance 4,149 F1: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026. F2: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 2 · 2026-09-01 · Grant · Acquired 164 · Balance 4,313 F4: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
F2: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F3: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F4: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2024 Filed Nov 6, 2024 00:48 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 6,606 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000950170-24-121742 · ownership.xml · derivative · entry 5 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 453,394 Underlying: Common Stock · 6,606 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares subject to the stock option vested and became exercisable with respect to 25% of the shares on the first anniversary of August 16, 2021 (the "Vesting Commencement Date") with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
| November 01, 2024 Filed Nov 6, 2024 00:48 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 6,606 | $48.97 | $323,495.82 |
DisclosureSEC source: 0000950170-24-121742 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,796 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 01, 2024 Filed Nov 6, 2024 00:48 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 6,606 | $21.65 | $143,019.90 |
DisclosureSEC source: 0000950170-24-121742 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000950170-24-112385 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 460,000 Underlying: Common Stock · 10,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares subject to the stock option vested and became exercisable with respect to 25% of the shares on the first anniversary of August 16, 2021 (the "Vesting Commencement Date") with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 10,000 | $46.28 | $462,800.00 |
DisclosureSEC source: 0000950170-24-112385 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,796 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,000 | $21.65 | $216,500.00 |
DisclosureSEC source: 0000950170-24-112385 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 00:04 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000950170-24-104196 · ownership.xml · derivative · entry 4 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 470,000 Underlying: Common Stock · 10,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Shares subject to the stock option vested and became exercisable with respect to 25% of the shares on the first anniversary of August 16, 2021 (the "Vesting Commencement Date") with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 00:04 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 243 | $35.30 | $8,577.90 |
DisclosureSEC source: 0000950170-24-104196 · ownership.xml · nonDerivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,796 F3 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F4 · price: The closing price on August 30, 2024 was used to calculate the withholding obligation. F1 · balance_after: Includes 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 00:04 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 10,000 | $35.30 | $353,000.00 |
DisclosureSEC source: 0000950170-24-104196 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,039 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 00:04 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,000 | $21.65 | $216,500.00 |
DisclosureSEC source: 0000950170-24-104196 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000950170-24-091069 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 480,000 Underlying: Common Stock · 10,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares subject to the stock option vested and became exercisable with respect to 25% of the shares on the first anniversary of August 16, 2021 (the "Vesting Commencement Date") with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 10,000 | $38.67 | $386,700.00 |
DisclosureSEC source: 0000950170-24-091069 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,039 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,000 | $21.65 | $216,500.00 |
DisclosureSEC source: 0000950170-24-091069 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 21:13 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000950170-24-081628 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 490,000 Underlying: Common Stock · 10,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares subject to the stock option vested and became exercisable with respect to 25% of the shares on the first anniversary of August 16, 2021 (the "Vesting Commencement Date") with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 21:13 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 10,000 | $32.49 | $324,900.00 |
DisclosureSEC source: 0000950170-24-081628 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,039 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 21:13 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,000 | $21.65 | $216,500.00 |
DisclosureSEC source: 0000950170-24-081628 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:11 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.26 | $0.00 |
DisclosureSEC source: 0000950170-24-069600 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 10,000 shares Expires 2032-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:11 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 10,000 | $32.00 | $320,000.00 |
DisclosureSEC source: 0000950170-24-069600 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,039 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:11 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,000 | $19.26 | $192,600.00 |
DisclosureSEC source: 0000950170-24-069600 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 28, 2024 Filed May 31, 2024 00:03 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $19.26 | $0.00 |
DisclosureSEC source: 0000950170-24-066881 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 30,000 shares Expires 2032-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 28, 2024 Filed May 31, 2024 00:03 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 30,000 | $32.00 | $960,000.00 |
DisclosureSEC source: 0000950170-24-066881 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,039 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 28, 2024 Filed May 31, 2024 00:03 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 30,000 | $19.26 | $577,800.00 |
DisclosureSEC source: 0000950170-24-066881 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 02:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 604 | $24.06 | $14,532.24 |
DisclosureSEC source: 0000950170-24-026773 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,039 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · balance_after: Includes 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.01 | $0.00 |
DisclosureSEC source: 0000950170-24-014874 · ownership.xml · derivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-02-09 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 9, 2024 over a four-year period. Read SEC document |
| December 22, 2023 Filed Dec 23, 2023 00:29 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.26 | $0.00 |
DisclosureSEC source: 0000950170-23-072771 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 10,000 shares Expires 2032-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 22, 2023 Filed Dec 23, 2023 00:29 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 10,000 | $32.00 | $320,000.00 |
DisclosureSEC source: 0000950170-23-072771 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,643 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 1,472 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 22, 2023 Filed Dec 23, 2023 00:29 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,000 | $19.26 | $192,600.00 |
DisclosureSEC source: 0000950170-23-072771 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,472 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 609 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-068368 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,643 F5 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F4 · balance_after: Includes 1,472 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023 and 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 609 | $25.97 | $15,815.73 |
DisclosureSEC source: 0000950170-23-068368 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,034 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on December 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: The Form 4 previously filed inadvertently overstated the number of shares held by 319. The number in Column 5 reflects the corrected amount. F4 · balance_after: Includes 1,472 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023 and 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:55 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 478 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-046803 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,744 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,472 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:55 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 478 | $33.10 | $15,821.80 |
DisclosureSEC source: 0000950170-23-046803 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,266 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,472 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:52 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,472 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007051 · doc4.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,788 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:52 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,472 | $19.86 | $29,233.92 |
DisclosureSEC source: 0000899243-23-007051 · doc4.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,316 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 01:02 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.06 | $0.00 |
DisclosureSEC source: 0000899243-23-005179 · doc4.xml · derivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030513 · doc4.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,844 F3 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements under the Purchase Plan. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 922 | $25.98 | $23,953.56 |
DisclosureSEC source: 0000899243-22-030513 · doc4.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 922 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2022. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Read SEC document |
| February 02, 2022 Filed Feb 12, 2022 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $19.26 | $0.00 |
DisclosureSEC source: 0000899243-22-005977 · doc4.xml · derivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 2, 2022, so that the total number of shares subject to this option becomes fully vested and exercisable on February 2, 2026. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000899243-21-035142 · doc4.xml · derivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-08-31 F1 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable with respect to 25% of the shares on the first anniversary of August 16, 2021 (the "Vesting Commencement Date") with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.